Fig. 6
From: A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants
In vivo antiviral activity of SY110. a The schematic illustration of experiment design. b The viral RNA-dependent RNA polymerase (RdRp) gene copies were quantified by probe-based RT-qPCR (n = 5–7) or c subgenomic envelope (sgE) mRNA copies were quantified by probe-based RT-qPCR (n = 5–7) or d viral titer quantification with plaque assay (n = 5–7). All data were obtained from three times of independent experiments and shown as mean ± SD. Statistical differences were determined with one-way analysis of variance (ANOVA) with Tukey’s multiple comparison test in b–d. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
